Thymosin Alpha-1 Safety in Adults Ages 30 to 49

HealthRX.com

Thymosin alpha-1 safety data are limited for adults aged 30 to 49

Print or save as PDF

Key numbers

  • risk ratio 0.72Fewer serious adverse events than comparator treatments in chronic hepatitis B trials (low certainty)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • risk ratio 0.47Fewer non-serious adverse events than comparator treatments in chronic hepatitis B trials (very low certainty)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.6 mgItalian Zadaxin label dose as an adjuvant to influenza vaccination, given subcutaneously or intramuscularly twice weeklySource: fda.gov, as cited Nov 7, 2026
  • 17 million dosesZadaxin doses given after marketing, per manufacturer-linked authors (company-side figure, not independent)Source: fda.gov, as cited Nov 7, 2026

See the public record for Thymalfasin

  • Drug / thymosin alpha-1 (thymalfasin), a 28-amino-acid immune-modulating peptide [2]
  • US status / Not FDA-approved; four US orphan drug designations, which are not approvals [2]
  • US-approved dose / None exists [2]
  • Dose in the Italian Zadaxin label / 1.6 mg subcutaneously or intramuscularly twice weekly [2]
  • Harms in hepatitis B trials / May have caused fewer serious and non-serious adverse events than comparator treatments, low to very low certainty [1]
  • Label cautions (Italy) / Contraindicated in pregnancy and breastfeeding; caution with allergy, autoimmune disease and other immune-modulating drugs [2]
  • FDA compounding concerns / Immunogenicity risk for certain routes, peptide-impurity and characterization problems [3]

What safety data exist

Thymosin alpha-1 is a 28-amino-acid peptide described as an immune modulator that augments T-cell function [2][4]. The main independent trial evidence comes from adults with chronic hepatitis B, so it does not establish safety for healthy adults aged 30 to 49 [1]. A 2026 Cochrane review pooled randomized trials in adults with chronic hepatitis B, testing thymosin alpha-1 alone or alongside interferon, lamivudine, entecavir or tenofovir against placebo, no treatment, or the same co-treatment [1].

What people on Reddit report

These are personal accounts from people who used thymosin alpha-1 and described how they felt during or after treatment. They are anecdotes, not measured results, and they vary widely.

Living_Mushroom_4735 · cfs

the first 3 days my lymphnodes all swoll and i slept horrible wich was kind of expected since it activates the immune system.

Reports swollen lymph nodes and poor sleep in the first days, then a decline in energy and function that continued after a single dose.

Read the source discussion

tansy20bartlett · cfs

It's susceptible to becoming contaminated with LPS (lipopolysacharides), which are extremely inflammatory, during the manufacturing process.

Suggests that reactions may come from contamination in unregulated supply rather than from the peptide itself. This is a claim, not a tested finding.

Read the source discussion

welshpudding · Immunology

I basically get more ill for a few days every time I take the TA1. So it's a bit of a hinderance to general work and life stuff.

Reports feeling worse for a few days after each dose, enough to interfere with work and daily life, and considering lower doses.

Read the source discussion

What the hepatitis B trials found about harm

The review's authors wrote that they are "not sure" whether thymosin alpha-1 helps [1]. On harms, it reported that thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. It also found a possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, and little to no effect on quality of life or on liver histology [1].

An older, very small pilot gave 7 people with chronic hepatitis B thymosin fraction 5 or thymosin alpha-1 and 5 people placebo, twice weekly for six months. No significant side effects were observed in either group [5].

Post-marketing reports and the FDA adverse-event database

FDA searched its adverse-event database on April 22, 2024 and found zero reports for thymosin alpha-1 [2]. A zero count is a count of reports, not a measured rate of reactions.

Authors tied to the manufacturer report that more than 4,400 people were enrolled in trials and that more than 17 million doses of Zadaxin were given after marketing, with adverse experiences described as "infrequent and mild" [2]. That description comes from the company side rather than an independent analysis.

What the Zadaxin label says

FDA has approved no thymosin alpha-1 product, so there is no US-approved dose [2]. In Italy, Zadaxin 1.6 mg powder is authorized as an adjuvant to influenza vaccination in immunocompromised people [2]. The Italian label's schedule is 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [2].

The Italian label says the product is not for children and is contraindicated in pregnancy and breastfeeding. It also lists caution for people with allergies or autoimmune disease and for those taking other immune-modulating drugs [2].

Other national approvals differ. India's authorization covers chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication, and Hong Kong also has an authorization [2]. FDA notes that a SciClone 2014 annual report claims authorizations in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, mostly for hepatitis B and as a vaccine adjuvant, which FDA said it could not independently verify [2]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [2].

Compounding status and FDA's safety concerns

A Drugs@FDA search found no US application for thymosin alpha-1. The four US orphan drug designations come from a separate process and are not approvals [2].

FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) lists thymosin alpha-1 in the "nominated but withdrawn" table. It had been in category 2, the group for substances with potential significant safety risks, and came off that list when the nominators withdrew [3]. FDA's concerns remain posted: a "significant risk for immunogenicity for certain routes of administration", peptide-impurity and characterization problems, and safety information "inadequate for the agency to sufficiently understand the extent of any safety issues" [3].

On FDA's list for outsourcing facilities (updated March 21, 2025) it falls in category 3, "nominated without adequate support" [6]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and FDA's category 1 policy of generally not acting against compounders when conditions are met does not apply to it [7][6].

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety [8]. Thymosin alpha-1 is also not one of the six peptides covered by HHS's October 2026 draft enforcement-discretion policy, and no FDA or HHS action allows its compounding [9].

The practical answer for an adult aged 30 to 49

No data separate out this age group. The best available harms data come from hepatitis B trials and from company-linked post-marketing reports, and FDA's own adverse-event database held no reports as of April 22, 2024 [1][2]. The Italian label's cautions (pregnancy, breastfeeding, allergy, autoimmune disease, other immune-modulating drugs) are the most specific safety guidance attached to the product [2]. FDA has also posted immunogenicity and characterization concerns about compounded versions [3].

Questions worth asking

Choose the questions you want to keep

Is thymosin alpha-1 safe for adults in their 30s and 40s?
No trial data are specific to this age group. In the 2026 Cochrane review of chronic hepatitis B trials, thymosin alpha-1 may have caused fewer serious events than comparators (risk ratio 0.72, 95% CI 0.53 to 0.99; low-certainty evidence) [1]. There is no US-approved product [2].
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application, and four orphan drug designations are not approvals [2]. FDA lists approvals in Italy, India and Hong Kong, and the European Medicines Agency holds only an orphan designation for hepatocellular carcinoma [2].
What side effects are reported with thymosin alpha-1?
The Cochrane review reported fewer non-serious adverse events than comparison treatments (risk ratio 0.47, 95% CI 0.27 to 0.83; very low certainty) [1]. FDA's adverse-event database search on April 22, 2024 returned zero reports, which is a count of reports rather than a rate [2]. Authors tied to the manufacturer describe adverse experiences as infrequent and mild across more than 17 million post-marketing doses [2].
What does the Italian label say about pregnancy and autoimmune disease?
The Italian Zadaxin label lists pregnancy and breastfeeding as contraindications and lists caution for people with allergies or autoimmune disease and for people taking other immune-modulating drugs [2]. FDA has approved no thymosin alpha-1 product, so there is no US label [2].
What does FDA say about compounded thymosin alpha-1?
FDA moved it to the nominated-but-withdrawn table on its significant-safety-risk page. Its posted concerns include immunogenicity risk for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency considered inadequate [3]. Its advisory committee voted 4 yes and 17 no on December 4, 2024 [8].
Is thymosin alpha-1 a banned substance in sport?
It is not named on WADA's 2026 Prohibited List. WADA does name thymosin-beta-4 and derivatives such as TB-500 in S2.3, which are different peptides [10].
Show all 13 referencesHide references
  1. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
  2. U.S. Food and Drug Administration.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  4. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  5. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. Official web page.
  10. World Anti-Doping Agency.
  11. Reddit participants. be careful about thymosin alpha-1 (r/cfs). Accessed 2026-11-11.
  12. Reddit participants. Thymosin alpha 1 daily vs twice weekly administration (r/Immunology). Accessed 2026-11-11.
  13. Reddit participants. Thymosin Alpha 1 Experiences & Dosing (r/Lyme). Accessed 2026-11-11.
Evidence overview for Thymosin Alpha-1 Safety in Adults Ages 30 to 49